DekaBank Deutsche Girozentrale raised its stake in shares of Bruker Co. (NASDAQ:BRKR - Free Report) by 32.4% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 307,040 shares of the medical research company's stock after buying an additional 75,220 shares during the quarter. DekaBank Deutsche Girozentrale owned about 0.21% of Bruker worth $21,516,000 at the end of the most recent reporting period.
Several other hedge funds also recently bought and sold shares of BRKR. TD Asset Management Inc lifted its stake in shares of Bruker by 7.4% during the first quarter. TD Asset Management Inc now owns 1,788,763 shares of the medical research company's stock valued at $168,036,000 after buying an additional 123,984 shares during the period. Atria Investments Inc acquired a new stake in shares of Bruker during the first quarter worth $1,142,000. Point72 Asset Management L.P. acquired a new stake in shares of Bruker during the second quarter worth $36,472,000. Epoch Investment Partners Inc. grew its position in shares of Bruker by 15.2% in the first quarter. Epoch Investment Partners Inc. now owns 466,865 shares of the medical research company's stock valued at $43,857,000 after purchasing an additional 61,429 shares during the period. Finally, Assenagon Asset Management S.A. increased its stake in Bruker by 1,694.4% in the second quarter. Assenagon Asset Management S.A. now owns 202,733 shares of the medical research company's stock valued at $12,936,000 after purchasing an additional 191,435 shares during the last quarter. Hedge funds and other institutional investors own 79.52% of the company's stock.
Bruker Stock Down 0.7 %
NASDAQ BRKR traded down $0.41 during trading hours on Tuesday, hitting $58.05. The company had a trading volume of 1,060,309 shares, compared to its average volume of 1,048,238. The firm's 50 day moving average is $64.60 and its 200 day moving average is $67.36. The company has a debt-to-equity ratio of 1.18, a current ratio of 1.65 and a quick ratio of 0.75. Bruker Co. has a fifty-two week low of $53.79 and a fifty-two week high of $94.86. The company has a market capitalization of $8.44 billion, a price-to-earnings ratio of 21.11, a P/E/G ratio of 2.52 and a beta of 1.18.
Bruker (NASDAQ:BRKR - Get Free Report) last posted its earnings results on Tuesday, August 6th. The medical research company reported $0.52 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.52. The business had revenue of $800.70 million during the quarter, compared to analyst estimates of $799.44 million. Bruker had a return on equity of 24.92% and a net margin of 11.29%. The company's revenue for the quarter was up 17.4% compared to the same quarter last year. During the same quarter last year, the firm earned $0.50 earnings per share. Sell-side analysts anticipate that Bruker Co. will post 2.61 earnings per share for the current fiscal year.
Bruker Dividend Announcement
The company also recently declared a quarterly dividend, which was paid on Monday, September 16th. Investors of record on Monday, September 2nd were issued a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a yield of 0.34%. The ex-dividend date of this dividend was Friday, August 30th. Bruker's payout ratio is 7.27%.
Wall Street Analysts Forecast Growth
A number of brokerages have issued reports on BRKR. Wolfe Research lowered Bruker from an "outperform" rating to a "peer perform" rating in a research note on Monday, September 30th. TD Cowen lowered their target price on shares of Bruker from $74.00 to $72.00 and set a "hold" rating for the company in a report on Wednesday, August 7th. Barclays started coverage on shares of Bruker in a research note on Tuesday, October 15th. They set an "overweight" rating and a $75.00 price target on the stock. Citigroup lowered their price objective on shares of Bruker from $95.00 to $80.00 and set a "buy" rating for the company in a research note on Wednesday, July 10th. Finally, Wells Fargo & Company initiated coverage on Bruker in a report on Tuesday, August 27th. They issued an "overweight" rating and a $78.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, Bruker presently has a consensus rating of "Moderate Buy" and an average price target of $80.82.
Read Our Latest Analysis on Bruker
About Bruker
(
Free Report)
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.
See Also
Before you consider Bruker, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bruker wasn't on the list.
While Bruker currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
